

ASX ANNOUNCEMENT

13 September 2022

## Appointment of Emily Slade as a Non-Executive Director

**HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce the appointment of Emily Slade as a Non-Executive Director, with immediate effect.

Throughout her executive career, Emily has gained broad experience across Legal and Business Affairs, Intellectual Property and Strategy, in a range of sectors including healthcare, logistics and technology. Emily has worked in a range of organisations from start-ups to SMEs as well as large public companies such as Ansell Limited.

Emily was most recently Head of Legal and Business Affairs at Rendr, a fulfilment technology company providing on demand delivery solutions and was previously Head of Legal at Deliveroo AU and Legal Counsel Asia Pacific at Ansell Limited.

HeraMED Chairman, Ron Weinberger said: “Emily brings highly relevant experience to HeraMED at a time when the commercialisation of the HeraMED technology platform is gathering momentum, underpinned by a rapidly growing number of commercial partnerships across Australasia, USA, Europe, and Israel.

“Throughout her career, Emily has gained significant experience in managing legal issues including, most relevantly, licence, supply and distribution agreements and the protection and capitalisation of intellectual property,” he said.

Non-Executive Director, Emily Slade said: “I am delighted to be joining the HeraMED Board and look forward to supporting the commercialisation of the unique and cutting edge HeraCARE technology.

“Growing up as part of the Slade Health Group, I have gravitated towards the healthcare sector and start-ups throughout my career and have accrued a broad network which I hope can complement and support HeraMED’s commercialisation strategy. I am excited about contributing to the future of HeraMED through my role on the Board,” she said.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

**HeraMED Limited**  
CEO and Co-Founder  
David Groberman  
M: +972 52 6991188  
E: [David@hera-med.com](mailto:David@hera-med.com)

**Company Secretary**  
Jonathan Hart  
T: +61 2 7251 1888  
E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Investors**  
Tim Chapman  
T: +61 419 897 062  
E: [tchapman@pacpartners.com.au](mailto:tchapman@pacpartners.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

**About HeraCARE**

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detect and prevention of potential risks.